Deciphera Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Deciphera Pharmaceuticals is an American biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. It was founded in 2003 and is headquartered in Waltham, Massachusetts.
Deciphera Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Deciphera Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Deciphera Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Deciphera Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Deciphera Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Deciphera Pharmaceuticals assets
Deciphera Pharmaceuticals cash flows

Deciphera Pharmaceuticals dividend policy

The company doesn't provide dividends

Deciphera Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
DCPH:USDeciphera PharmaceuticalsCommon share-US24344T1016$15.23
Deciphera Pharmaceuticals news
04.05.2022
Deciphera Pharmaceuticals' GAAP loss for 3 months of 2022 was $46.892 million, down 23.5% from $61.298 million in the previous year. Revenue increased 16.2% to $29.223 million compared to $25.156 million a year earlier.
Source: {source} pictogram investors.deciphera.com
Pictogram next
09.02.2022
Deciphera Pharmaceuticals' GAAP loss for 2021 was $299.964 million, up 12.6% from $266.489 million in the previous year. Revenue increased 2.3 times to $96.148 million from $42.087 million a year earlier.
Source: {source} pictogram investors.deciphera.com
Pictogram next
21.12.2021
MHRA has approved QINLOCK from Deciphera Pharmaceuticals. QINLOCK is indicated for the treatment of advanced gastrointestinal stromal tumors in adults who have previously received treatment with three or more kinase inhibitors.
Source: {source} pictogram investors.deciphera.com
Pictogram next
22.11.2021
Deciphera Pharmaceuticals has received European Commission approval for Qinlock. The drug is used to treat adults with advanced gastrointestinal stromal tumors who have previously been treated with three or more kinase inhibitors.
Source: {source} pictogram investors.deciphera.com
Pictogram next
All Deciphera Pharmaceuticals news
General information
Company nameDeciphera Pharmaceuticals
Tags#biotechnology, #cancer treatment
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address200 Smith Street Waltham, MA 02451 United States
Mailing address200 Smith Street Waltham, MA 02451 United States
Websiteinvestors.deciphera.com
Information disclosurewww.sec.gov